CJC-1295 vs GDF-11
Side-by-Side Comparison
| Attribute | Cjc 1295 | Gdf 11 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Regenerative |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | GDF-11 signals through activin type II receptors (ActRIIA and ActRIIB) and downstream SMAD2/3 transcription factors. |
| Evidence Rating | D — Preclinical | D — Preclinical / Conflicting Data |
| Clinical Status | Research-only / Not approved for human use | Preclinical only. No human clinical trials. Highly controversial preclinical results. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | No human safety data exists; Shares 90% homology with myostatin; may cause muscle wasting at high doses |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~12.5 kDa (mature dimer) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | N/A |
Overview
CJC-1295 and GDF-11 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
GDF-11 — Mechanism & Evidence
GDF-11 is a member of the TGF-β superfamily that gained widespread attention after a 2013 Harvard study suggested it could reverse age-related cardiac hypertrophy when young blood was transfused into old mice (parabiosis). Subsequent research has been highly controversial, with conflicting reports on whether GDF-11 levels decline with age and whether supplementation is beneficial or harmful. The "young blood factor" narrative has been significantly challenged by replication failures and contradictory data.
Key claims: Reverses age-related cardiac hypertrophy; Promotes neurogenesis and brain rejuvenation; Improves muscle regeneration.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
GDF-11 is also researched for: Regenerative Medicine.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
GDF-11: No human safety data exists Shares 90% homology with myostatin; may cause muscle wasting at high doses TGF-β superfamily members have complex dose-dependent effects that can be beneficial or harmful
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.